Foundation Medicine (FMI) Scheduled to Post Earnings on Tuesday

Foundation Medicine (NASDAQ:FMI) will be posting its quarterly earnings results after the market closes on Tuesday, February 20th. Analysts expect Foundation Medicine to post earnings of ($0.99) per share for the quarter.

Foundation Medicine (NASDAQ FMI) opened at $63.70 on Tuesday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.03 and a current ratio of 2.24. Foundation Medicine has a 12 month low of $22.40 and a 12 month high of $75.20. The stock has a market capitalization of $2,310.00, a P/E ratio of -14.25 and a beta of -0.03.

In related news, insider Vincent A. Miller sold 4,400 shares of Foundation Medicine stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $75.00, for a total transaction of $330,000.00. Following the sale, the insider now directly owns 97,722 shares in the company, valued at $7,329,150. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Evan/ Fa Jones sold 6,500 shares of Foundation Medicine stock in a transaction that occurred on Wednesday, December 6th. The shares were sold at an average price of $60.66, for a total value of $394,290.00. Following the sale, the director now owns 19,652 shares in the company, valued at $1,192,090.32. The disclosure for this sale can be found here. Insiders have sold 228,717 shares of company stock worth $14,987,592 over the last three months. Insiders own 2.70% of the company’s stock.

Several equities analysts have recently issued reports on the company. BidaskClub cut Foundation Medicine from a “buy” rating to a “hold” rating in a research note on Tuesday, January 16th. Zacks Investment Research raised Foundation Medicine from a “hold” rating to a “buy” rating and set a $66.00 target price on the stock in a research note on Wednesday, December 6th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Foundation Medicine has a consensus rating of “Hold” and a consensus target price of $52.25.

ILLEGAL ACTIVITY WARNING: This article was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://www.americanbankingnews.com/2018/02/13/foundation-medicine-fmi-scheduled-to-post-earnings-on-tuesday.html.

About Foundation Medicine

Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.

Earnings History for Foundation Medicine (NASDAQ:FMI)

Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply